In preclinical models, MAPK/ERK kinase (MEK) inhibition is associated with upregulation of major histocompatibility complex (MHC)-1 on cancer cells and infiltration of T cells in tumors, leading to enhanced anti-PD-L1 activity. The gene discussed is CD274; the disease is cancer.